Effects of Altitude on Single-Breath Diffusing Capacity for Carbon Monoxide
DLCO
1 other identifier
observational
23
1 country
1
Brief Summary
The purpose of this study is to further understand the effects of altitude on the physiology of gas exchange in the pulmonary microcirculation in normal subjects and in people with chronic obstructive pulmonary disease (COPD) measured as the single-breath diffusing capacity for carbon monoxide (DLCOsb). The study will determine a mathematical formula to allow for altitude corrections in both study populations to be used clinically in pulmonary labs.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Aug 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 28, 2017
CompletedFirst Posted
Study publicly available on registry
August 1, 2017
CompletedStudy Start
First participant enrolled
August 10, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2019
CompletedFebruary 12, 2020
February 1, 2020
10 months
July 28, 2017
February 11, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Effect of altitude on measured diffusing capacity for carbon monoxide
3 weeks
Secondary Outcomes (1)
Comparison of a novel inert gas technique for measuring alveolar volume with body plethysmography
4 months
Study Arms (2)
Healthy subjects
Healthy subjects
Subjects with COPD
Subjects with a diagnosis of COPD
Eligibility Criteria
Men and women, ages 20-80, both healthy subjects and those with a diagnosis of COPD.
You may qualify if:
- Ages 20- 80 years
- Subjects must be either healthy or have been diagnosed with COPD
You may not qualify if:
- Anemia (hemoglobin \< 10.0 g/dL)
- Carboxyhemoglobin \> 3%
- Active smoking
- Heart disease or heart failure
- Pulmonary hypertension
- COPD exacerbation
- Pneumothroax within 6 months
- Bullous emphysema on chest imaging (Chest X-ray or CT)
- Supplemental oxygen use
- Diabetes mellitus
- Alcohol dependence
- Non-English speaking
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Intermountain Health Care, Inc.lead
- University of Utahcollaborator
Study Sites (1)
Intermountain Medical Center
Murray, Utah, 84157, United States
Related Publications (1)
Hegewald MJ, DeCato TW, Weaver LK, Jensen RL. Effect of barometric pressure on single-breath carbon monoxide diffusing capacity. Respir Physiol Neurobiol. 2023 Feb;308:103997. doi: 10.1016/j.resp.2022.103997. Epub 2022 Nov 17.
PMID: 36402362DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Matt Hegewald, MD
Intermountain Health Care, Inc.
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Adjunct Associate Professor, University of Utah
Study Record Dates
First Submitted
July 28, 2017
First Posted
August 1, 2017
Study Start
August 10, 2017
Primary Completion
June 15, 2018
Study Completion
July 1, 2019
Last Updated
February 12, 2020
Record last verified: 2020-02
Data Sharing
- IPD Sharing
- Will not share